Recent Updates
Recently added Catalysts
ESTA Positive Sentiment

Establishment Labs® Reports Third Quarter 2026 Financial Results

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Establishment Labs Holdings Inc. reported its financial results for Q3 2026. The company highlighted a new supply agreement with NuSil to enhance manufacturing capacity. Additionally, it received FDA approval for a smaller version of its Motiva implant, indicating growth potential in breast aesthetics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Announced a new supply agreement with NuSil.
  • Received FDA approval for additional smaller Motiva implant.

Full Press Release Details

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2026. Third Quarter Business Highlights Announced a new supply agreement with NuSil to support long-term manufacturing capacity and future growth. Received FDA approval for additional smaller Motiva implant

Frequently Asked Questions

What were the financial results for Q3 2026?

Establishment Labs announced its Q3 2026 financial results, highlighting key agreements.

What new agreement did Establishment Labs announce?

The company announced a supply agreement with NuSil for manufacturing support.

What FDA approval did Establishment Labs receive?

They received FDA approval for an additional smaller Motiva implant.

What is the focus of Establishment Labs?

The company focuses on women's health, particularly in breast aesthetics.

ShareAdd on Google
Tags: ESTA Establishment Labs Motiva implant FDA approval NuSil breast aesthetics
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$71M liquidity · $6M/mo burn
~10 mo
Medium dilution risk